Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use: Dissecting the Evidence

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 5, 2013, Pages 458-464

  Johnson, David A ^a   Oldfield, Edward C ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BREAST CANCER RESISTANCE PROTEIN; CALCIUM; CLOPIDOGREL; CYANOCOBALAMIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; FERRITIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; MAGNESIUM; METHOTREXATE; NONHEME IRON PROTEIN; PROTON PUMP INHIBITOR;

ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BACTERIAL PERITONITIS; BLOATING; BONE DENSITY; CALCIUM ABSORPTION; CALCIUM INTAKE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMPETITIVE INHIBITION; DELAYED HYPERSENSITIVITY; DIARRHEA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FERRITIN BLOOD LEVEL; FRAGILITY FRACTURE; HUMAN; HYPOMAGNESEMIA; INFECTION RISK; INFLAMMATION; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; LONG TERM EXPOSURE; MALABSORPTION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMALL INTESTINAL BACTERIAL OVERGROWTH; STOMACH ABSORPTION; STOMACH ACID SECRETION; STOMACH SECRETION; SYSTEMATIC REVIEW (TOPIC);

HUMANS; PROTON PUMP INHIBITORS;

EID: 84876727294     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.031     Document Type: Article

References (76)

1. Gatyas G. IMS health reports 2009 Accessed September 2012. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=d690a27e9d5b7210VgnVCM100000ed152ca2RCRD&vgnextfmt.
2. Bezwoda W., Charlton R., Bothwell T., et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med 1978, 92:108-116.
3. Conrad M.E., Schade S.G. Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. Gastroenterology 1968, 55:35-43.
4. McColl K.E. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(Suppl 2):S5-S9.
5. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992, 6:399-406.
6. Peura D.A. Nutrient malabsorption and fracture risk. Gastroenterol Hepatol 2011, 7:4-6.
7. Sarzynski E., Puttarajappa C., Xie Y., et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011, 56:2243-2253.
8. Wright M.J., Sullivan R.R., Gaffney-Stomberg E., et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010, 25:2205-2211.
9. Hansen K.E., Jones A.N., Lindstrom J.M., et al. Do proton pump inhibitors decrease calcium absorption?. J Bone Miner Res 2010, 25:2510-2519.
10. Accessed September 2012. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm.
11. Johnson D.A. Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Curr Gastroenterol Rep 2010, 12:167-174.
12. Khalili H., Huang E.S., Jacobson B.C., et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012, 344:e372.
13. Ngamruengphong S., Leontiadis G.I., Radhi S., et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011, 106:1209-1218.
14. Targownik L.E., Lix L.M., Leung S., et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896-904.
15. Gray S.L., LaCroix A.Z., Larson J., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170:765-771.
16. Targownik L.E., Leslie W.D., Davison K.S., et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012, 107:1361-1369.
17. Jefferies K.C., Cipriano D.J., Forgac M. Function structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys 2008, 476:33-42.
18. Mizunashi K., Furukawa Y., Katano K., et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21-25.
19. Epstein M., McGrath S., Law F. Proton pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006, 355:1834-1836.
20. Broeren M.A., Geerdink E.A., Vader H.L., et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009, 151:755-756.
21. MacKay J.D., Bladon P.T. Hypomagnesemia due to proton pump inhibitor therapy: a clinical case series. QJM 2010, 103:387-395.
22. Hess M.W., Hoenderop J.G., Bindels R.J., et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012, 36:405-413.
23. Accessed September 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm.
24. Yang Y.X., Metz D.C. Safety of proton pump inhibitor exposure. Gastroenterology 2010, 139:1115-1127.
25. Heidelbaugh J.J., Kim A.H., Chang R., et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012, 5:219-232.
26. Peura D.A. Nutrient malabsorption and fracture risk. Gastroenterol Hepatol 2011, 7:4-6.
27. Kazui M., Nishiya Y., Ishizuka T., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010, 38:92-99.
28. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
29. Mega J.L., Simon T., Anderson J.L., et al. CYP2C19 genetic variants and clinical outcomes with clopidogrel: a collaborative meta-analysis. Circulation 2009, 120:S598-S599.
30. Hwang S.J., Jeong Y.H., Kim J.S., et al. The cytochrome 2C19*2 and *3 alleles attenuate response to cloprodogrel similarly in east Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011, 127:23-28.
31. Desta Z., Zhao X., Shin J.G., et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913-958.
32. Accessed September 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm.
33. Accessed September 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm.
34. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
35. Ray W.A., Murray K.T., Griffin M.R., et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010, 152:337-345.
36. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008, 103:2890-2907.
37. Kwok C.S., Jeevanantham V., Dawn B., et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 2012 Mar 29, Epub ahead of print.
38. Parri M.S., Gianetti J., Dushpanova A., et al. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol 2012 Jun 22, Epub ahead of print.
39. Frelinger A.L., Lee R.D., Mulford D.J., et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 2012, 59:1304-1311.
40. Banerjee S., Weideman R.A., Weideman M.W., et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011, 107:871-878.
41. van Boxel O.S., van Oijen M.G., Hagenaars M.P., et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010, 105:2430-2436. quiz, 2437.
42. Johnson D.A. Concomitant use of PPIs and antiplatelet therapy. Gastroenterol Hepatol 2011, 7:7-10.
43. Kwok C.S., Loke Y.K. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf 2012, 35:127-139.
44. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
45. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167:950-955.
46. Herzig S.J., Howell M.D., Ngo L.H., et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009, 301:2120-2128.
47. Giuliano C., Wilhelm S.M., Kale-Pradhan P.B. Are proton pump inhibitors associated with the development of community acquired pneumonia?. A meta-analysis. Expert Rev Clin Pharmacol 2012, 5:337-344.
48. Hermos J.A., Young M.M., Fonda J.R., et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012, 54:33-42.
49. Johnstone J., Nerenberg K., Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010, 31:1165-1177.
50. Sarkar M., Hennessy S., Yang Y.X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008, 149:391-398.
51. Dial M.S. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009, 104(Suppl 2):S10-S16.
52. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056.
53. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
54. Janarthanan S., Ditah I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107:1001-1010.
55. Khanna S., Aronson S.L., Kammer P.P., et al. Gastric acid suppression and outcomes in Clostridium difficile infection: a population based study. Mayo Clin Proc 2012, 87:636-642.
56. Leonard A.D., Ho K.M., Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalized patients: a case-controlled study. Intern Med J 2012, 42:591-594.
57. McCollum D.L., Rodriguez J.M. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 2012, 10:581-592.
58. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
59. DuPont H.L. Traveller's diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006, 66:303-314.
60. Cobelens F.G., Leentvaar-Kuijpers A., Kleijnen J., et al. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Trop Med Int Health 1998, 3:896-903.
61. Bavishi C., DuPont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34:1269-1281.
62. Lombardo L., Foti M., Ruggia O., et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010, 8:504-508.
63. Compare D., Pica L., Rocco A., et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011, 41:380-386.
64. Choung R.S., Ruff K.C., Malhotra A., et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011, 33:1059-1067.
65. Ratuapli S.K., Ellington T.G., O'Neill M.T., et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012, 107:730-735.
66. Bajaj J.S., Zadvornova Y., Heuman D.M., et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009, 104:1130-1134.
67. Campbell M.S., Obstein K., Reddy K.R., et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008, 53:394-398.
68. Trikudanathan G., Israel J., Cappa J., et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011, 65:674-678.
69. Bajaj J.S., Ratliff S.M., Heuman D.M., et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012, 36:866-874.
70. Gupta A., Dhiman R.K., Kumari S., et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010, 53:849-855.
71. Sierra F., Suarez M., Rey M., et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007, 26:545-553.
72. Accessed September 2012. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm284421.htm.
73. Breedveld P., Zelcer N., Pluim D., et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004, 64:5804-5811.
74. Joerger M., Huitema A.D., van den Bongard H.J., et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006, 62:71-80.
75. Suzuki K., Doki K., Homma M., et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009, 67:44-49.
76. Bezabeh S., Mackey A.C., Kluetz P., et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 2012, 17:550-554.